Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hypoxia 4 Uterine Cervical Neoplasms 3 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Hypoxic Tumours 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Adenosquamous 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Sunitinib 145 Nivolumab 144 pembrolizumab 132 Sorafenib 84 Bevacizumab 77 Everolimus 74 cabozantinib 71 pazopanib 65 Axitinib 65 Ipilimumab 62 aldesleukin 52 Magnetic Resonance Spectroscopy 45 Cyclophosphamide 40 Interleukin-2 38 lenvatinib 37 Specimen Handling 36 Radiosurgery 36 Interferon-alpha 32 atezolizumab 30 temsirolimus 27 belzutifan 24 Gemcitabine 23 fludarabine phosphate 22 avelumab 22 Radiotherapy 19 Interferon alpha-2 19 Biopsy 18 fludarabine 17 durvalumab 17 Nephrectomy 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Renal Cell × fluoroazomycin arabinoside × Clear all

NCT03955393 2020-12-22

FAZA

IRCCS San Raffaele

Carcinoma, Renal Cell, Lymphatic Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡